Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

NCT01359566 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

228

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: Arbaclofen placarbil 15 mg BID
DRUG: Placebo
DRUG: Arbaclofen placarbil 30 mg BID
DRUG: Arbaclofen placarbil 45 mg BID

Sponsor

XenoPort, Inc.